Austria	O
,	O
Deutsch	O
,	O
Czech	O
Republic	O
,	O
Čeština	O
,	O
Germany	O
,	O
Deutsch	O
,	O
Luxembourg	O
,	O
Français	O
Nederlands	O
Spain	O
,	O
Español	O
,	O
Switzerland	O
,	O
Deutsch	O
,	O
Turkey	O
,	O
Türk	O
,	O
Robert	O
J.	O
Hugin	O
,	O
Executive	O
Chairman	O
,	O
Mr.	O
Hugin	O
serves	O
as	O
Celgene	O
's	O
Executive	O
Chairman	O
,	O
.	O
He	O
assumed	O
that	O
role	O
on	O
March	O
1	O
,	O
2016	O
.	O
Before	O
serving	O
as	O
Executive	O
Chairman	O
,	O
,	O
Mr.	O
Hugin	O
served	O
as	O
Celgene	O
's	O
Chief	O
Executive	O
Officer	O
,	O
,	O
a	O
position	O
he	O
held	O
since	O
June	O
2010	O
and	O
Celgene	O
's	O
Chairman	O
,	O
a	O
position	O
he	O
has	O
held	O
since	O
June	O
2011	O
.	O
Mr.	O
Hugin	O
served	O
as	O
President	O
and	O
Chief	O
Operating	O
Officer	O
,	O
from	O
May	O
2006	O
to	O
June	O
2010	O
,	O
and	O
was	O
elected	O
by	O
the	O
Board	O
of	O
Directors	O
to	O
serve	O
as	O
a	O
Director	O
in	O
December	O
2001	O
.	O
Mr.	O
Hugin	O
joined	O
Celgene	O
in	O
June	O
1999	O
as	O
Senior	O
Vice	O
President	O
and	O
Chief	O
Financial	O
Officer	O
.	O
Mr.	O
Hugin	O
is	O
a	O
past	O
Chairman	O
of	O
the	O
Board	O
of	O
The	O
Pharmaceutical	O
Research	O
and	O
Manufacturers	O
of	O
America	O
and	O
is	O
a	O
member	O
of	O
the	O
Board	O
of	O
Trustees	O
of	O
Princeton	O
University	O
,	O
The	O
Medicines	O
Company	O
,	O
and	O
The	O
Darden	O
Foundation	O
,	O
University	O
of	O
Virginia	O
.	O
He	O
also	O
serves	O
as	O
a	O
member	O
of	O
the	O
Board	O
of	O
Trustees	O
of	O
Atlantic	O
Health	O
System	O
and	O
of	O
Family	O
Promise	O
,	O
a	O
national	O
non-profit	O
network	O
assisting	O
homeless	O
families	O
.	O
Prior	O
to	O
joining	O
Celgene	O
,	O
Mr.	O
Hugin	O
was	O
a	O
Managing	O
Director	O
with	O
J.P.	O
Morgan	O
&	O
Co.	O
.	O
Inc.	O
.	O
Mr.	O
Hugin	O
received	O
an	O
AB	O
degree	O
from	O
Princeton	O
University	O
in	O
1976	O
and	O
an	O
MBA	O
from	O
the	O
University	O
of	O
Virginia	O
in	O
1985	O
and	O
served	O
as	O
a	O
United	O
States	O
Marine	O
Corps	O
infantry	O
officer	O
during	O
the	O
intervening	O
period	O
.	O
Story	O
on	O
Robert	O
Hugin	O
from	O
The	O
Street	O
,	O
Mark	O
J.	O
Alles	O
,	O
Chief	O
Executive	O
Officer	O
,	O
Mr.	O
Alles	O
serves	O
as	O
Celgene	O
's	O
Chief	O
Executive	O
Officer	O
,	O
.	O
He	O
assumed	O
the	O
role	O
on	O
March	O
1	O
,	O
2016	O
.	O
Previously	O
he	O
served	O
as	O
President	O
and	O
Chief	O
Operating	O
Officer	O
,	O
.	O
Mr.	O
Alles	O
served	O
as	O
Executive	O
Vice	O
President	O
and	O
Global	O
Head	O
of	O
Hematology	O
and	O
Oncology	O
from	O
December	O
2012	O
until	O
July	O
2014	O
,	O
following	O
his	O
promotion	O
to	O
Executive	O
Vice	O
President	O
and	O
Chief	O
Commercial	O
Officer	O
in	O
February	O
2012	O
.	O
Mr.	O
Alles	O
joined	O
Celgene	O
in	O
April	O
2004	O
and	O
served	O
as	O
Vice	O
President	O
,	O
Global	O
Marketing	O
until	O
March	O
2009	O
when	O
he	O
became	O
President	O
of	O
the	O
Americas	O
Region	O
.	O
Responsibility	O
for	O
commercial	O
operations	O
in	O
Japan	O
and	O
the	O
Asia	O
Pacific	O
Region	O
was	O
added	O
in	O
July	O
2011	O
.	O
Mr.	O
Alles	O
previously	O
served	O
as	O
Vice	O
President	O
for	O
the	O
U.S.	O
Oncology	O
Business	O
Unit	O
of	O
Aventis	O
Pharmaceuticals	O
and	O
in	O
other	O
commercial	O
sales	O
and	O
marketing	O
management	O
roles	O
over	O
an	O
11-year	O
period	O
with	O
Aventis	O
.	O
After	O
earning	O
his	O
B.S.	O
degree	O
from	O
Lock	O
Haven	O
University	O
of	O
Pennsylvania	O
and	O
serving	O
as	O
a	O
Captain	O
in	O
the	O
United	O
States	O
Marine	O
Corps	O
,	O
Mr.	O
Alles	O
began	O
his	O
29-year	O
career	O
in	O
the	O
pharmaceutical	O
industry	O
at	O
Bayer	O
and	O
worked	O
at	O
Centocor	O
before	O
its	O
acquisition	O
by	O
Johnson	O
&	O
Johnson	O
.	O
Mr.	O
Alles	O
is	O
a	O
member	O
of	O
the	O
Celgene	O
Board	O
of	O
Directors	O
,	O
the	O
Trustees	O
for	O
the	O
Healthcare	O
Institute	O
of	O
New	O
Jersey	O
-LRB-	O
HINJ	O
-RRB-	O
,	O
the	O
Board	O
of	O
the	O
Biotechnology	O
Innovation	O
Organization	O
-LRB-	O
BIO	O
-RRB-	O
,	O
and	O
the	O
Board	O
of	O
Gilda	O
's	O
Club	O
NYC	O
,	O
a	O
not-for-profit	O
organization	O
helping	O
the	O
families	O
of	O
people	O
living	O
with	O
cancer	O
.	O
Jacqualyn	O
A.	O
Fouse	O
,	O
PhD	O
,	O
President	O
and	O
Chief	O
Operating	O
Officer	O
,	O
Dr.	O
Fouse	O
was	O
promoted	O
to	O
President	O
and	O
Chief	O
Operating	O
Officer	O
,	O
on	O
March	O
1	O
,	O
2016	O
.	O
In	O
February	O
2016	O
,	O
Dr.	O
Fouse	O
was	O
elected	O
to	O
the	O
Board	O
of	O
Directors	O
.	O
Previously	O
she	O
was	O
President	O
,	O
Global	O
Hematology	O
and	O
Oncology	O
since	O
July	O
2014	O
.	O
Dr.	O
Fouse	O
joined	O
the	O
Company	O
in	O
September	O
2010	O
as	O
Senior	O
Vice	O
President	O
and	O
Chief	O
Financial	O
Officer	O
and	O
became	O
Executive	O
Vice	O
President	O
and	O
Chief	O
Financial	O
Officer	O
,	O
in	O
February	O
2012	O
.	O
Before	O
Celgene	O
,	O
Dr.	O
Fouse	O
served	O
as	O
Chief	O
Financial	O
Officer	O
of	O
Bunge	O
Limited	O
,	O
a	O
leading	O
global	O
agribusiness	O
and	O
food	O
company	O
-LRB-	O
Bunge	O
-RRB-	O
,	O
starting	O
in	O
July	O
2007	O
.	O
Before	O
Bunge	O
,	O
Dr.	O
Fouse	O
was	O
at	O
Alcon	O
Laboratories	O
serving	O
as	O
Senior	O
Vice	O
President	O
,	O
Chief	O
Financial	O
Officer	O
,	O
and	O
Head	O
of	O
Corporate	O
Strategy	O
at	O
Alcon	O
Laboratories	O
between	O
2002	O
and	O
2007	O
.	O
Dr.	O
Fouse	O
was	O
the	O
Chief	O
Financial	O
Officer	O
at	O
Swissair	O
Group	O
from	O
2001	O
to	O
2002	O
.	O
Dr.	O
Fouse	O
held	O
a	O
variety	O
of	O
senior	O
finance	O
positions	O
at	O
Nestlé	O
S.A.	O
from	O
1993	O
to	O
2001	O
,	O
including	O
serving	O
as	O
Group	O
Treasurer	O
of	O
Nestlé	O
from	O
1999	O
to	O
2001	O
.	O
Dr.	O
Fouse	O
also	O
worked	O
in	O
finance	O
at	O
Alcon	O
from	O
1986	O
to	O
1993	O
and	O
held	O
several	O
positions	O
,	O
including	O
Manager	O
Corporate	O
Investments	O
and	O
Domestic	O
Finance	O
.	O
Earlier	O
in	O
her	O
career	O
,	O
she	O
worked	O
at	O
Celanese	O
Chemical	O
and	O
LTV	O
Aerospace	O
and	O
Defense	O
.	O
Dr.	O
Fouse	O
earned	O
a	O
B.A.	O
and	O
an	O
M.A.	O
in	O
Economics	O
and	O
a	O
Ph.D.	O
in	O
Finance	O
from	O
the	O
University	O
of	O
Texas	O
at	O
Arlington	O
.	O
Since	O
2010	O
,	O
Dr.	O
Fouse	O
has	O
served	O
as	O
a	O
member	O
of	O
the	O
Board	O
of	O
Directors	O
of	O
Dick	O
's	O
Sporting	O
Goods	O
-LRB-	O
chairperson	O
of	O
the	O
audit	O
committee	O
-RRB-	O
,	O
an	O
NYSE-listed	O
company	O
.	O
She	O
served	O
on	O
the	O
Board	O
of	O
Directors	O
of	O
the	O
Perrigo	O
Company	O
-LRB-	O
member	O
of	O
the	O
audit	O
committee	O
-RRB-	O
,	O
an	O
NYSE-listed	O
company	O
,	O
from	O
November	O
2012	O
to	O
April	O
2016	O
.	O
Peter	O
N.	O
Kellogg	O
,	O
Executive	O
Vice	O
President	O
and	O
Chief	O
Financial	O
Officer	O
,	O
Mr.	O
Kellogg	O
serves	O
as	O
Executive	O
Vice	O
President	O
and	O
Chief	O
Financial	O
Officer	O
,	O
.	O
Mr.	O
Kellogg	O
joined	O
Celgene	O
in	O
July	O
2014	O
.	O
Previously	O
,	O
he	O
was	O
Chief	O
Financial	O
Officer	O
and	O
Executive	O
Vice	O
President	O
of	O
Merck	O
&	O
Co.	O
.	O
Inc.	O
since	O
August	O
2007	O
.	O
From	O
2000	O
to	O
2007	O
,	O
Mr.	O
Kellogg	O
served	O
as	O
Chief	O
Financial	O
Officer	O
and	O
Executive	O
Vice	O
President	O
of	O
Finance	O
at	O
Biogen	O
.	O
Before	O
that	O
,	O
he	O
served	O
as	O
Senior	O
Vice	O
President	O
,	O
PepsiCo	O
E-Commerce	O
at	O
PepsiCo	O
Inc.	O
from	O
March	O
to	O
July	O
2000	O
and	O
as	O
Senior	O
Vice	O
President	O
and	O
Chief	O
Financial	O
Officer	O
,	O
Frito-Lay	O
International	O
,	O
from	O
March	O
1998	O
to	O
March	O
2000	O
.	O
From	O
1987	O
to	O
1998	O
,	O
he	O
served	O
in	O
a	O
variety	O
of	O
senior	O
financial	O
,	O
international	O
and	O
general	O
management	O
positions	O
at	O
PepsiCo	O
and	O
Pepsi-Cola	O
International	O
,	O
Pepsi-Cola	O
North	O
America	O
,	O
and	O
Frito-Lay	O
International	O
divisions	O
.	O
Prior	O
to	O
joining	O
PepsiCo	O
,	O
Mr.	O
Kellogg	O
was	O
a	O
senior	O
consultant	O
with	O
Arthur	O
Andersen	O
&	O
Co.	O
and	O
Booz	O
Allen	O
&	O
Hamilton	O
.	O
Since	O
March	O
2007	O
,	O
Mr.	O
Kellogg	O
has	O
been	O
a	O
Director	O
of	O
Metabolix	O
,	O
Inc.	O
,	O
a	O
public	O
bioscience	O
and	O
engineering	O
company	O
focused	O
on	O
providing	O
sustainable	O
solutions	O
to	O
the	O
plastics	O
and	O
chemicals	O
industries	O
.	O
He	O
received	O
a	O
BSE	O
from	O
Princeton	O
University	O
in	O
1978	O
and	O
an	O
MBA	O
from	O
The	O
Wharton	O
School	O
in	O
1982	O
.	O
Scott	O
A.	O
Smith	O
,	O
President	O
,	O
Global	O
Inflammation	O
and	O
Immunology	O
,	O
Mr.	O
Smith	O
serves	O
as	O
President	O
,	O
Global	O
Inflammation	O
and	O
Immunology	O
,	O
.	O
Previously	O
he	O
was	O
Senior	O
Vice	O
President	O
,	O
Global	O
Head	O
of	O
I	O
&	O
I	O
.	O
He	O
joined	O
Celgene	O
in	O
2008	O
as	O
Vice	O
President	O
,	O
Global	O
Marketing	O
Inflammation	O
and	O
Immunology	O
.	O
From	O
2003	O
to	O
2008	O
Mr.	O
Smith	O
was	O
with	O
Biovail	O
,	O
holding	O
positions	O
of	O
General	O
Manager	O
Biovail	O
U.S.	O
,	O
General	O
Manager	O
Biovail	O
Canada	O
and	O
Global	O
Commercial	O
Head	O
.	O
As	O
Global	O
Commercial	O
Head	O
for	O
Biovail	O
,	O
he	O
was	O
responsible	O
for	O
global	O
revenue	O
generation	O
,	O
global	O
commercial	O
strategies	O
,	O
business	O
development	O
strategy	O
,	O
and	O
input	O
into	O
global	O
regulatory	O
and	O
clinical	O
development	O
strategies	O
.	O
Prior	O
to	O
Biovail	O
,	O
Mr.	O
Smith	O
was	O
with	O
Pharmacia	O
-LRB-	O
formerly	O
Upjohn	O
-RRB-	O
for	O
16	O
years	O
where	O
he	O
held	O
various	O
positions	O
including	O
Vice	O
President	O
U.S.	O
Sales	O
,	O
Vice	O
President	O
Marketing	O
Europe	O
based	O
in	O
Paris	O
,	O
Vice	O
President	O
and	O
Commercial	O
Lead	O
for	O
Canada	O
based	O
in	O
Toronto	O
,	O
and	O
Commercial	O
and	O
Regulatory	O
Head	O
for	O
South	O
East	O
Asia	O
based	O
in	O
Hong	O
Kong	O
.	O
Mr.	O
Smith	O
holds	O
a	O
BSc	O
in	O
Chemistry	O
and	O
an	O
HBSc	O
in	O
Pharmacology	O
and	O
Toxicology	O
from	O
the	O
University	O
of	O
Western	O
Ontario	O
and	O
a	O
Masters	O
of	O
International	O
Business	O
Management	O
from	O
the	O
American	O
Graduate	O
School	O
of	O
International	O
Management	O
-LRB-	O
Thunderbird	O
-RRB-	O
.	O
Michael	O
Pehl	O
,	O
President	O
,	O
Hematology	O
&	O
Oncology	O
,	O
Mr.	O
Pehl	O
serves	O
as	O
President	O
,	O
Global	O
Hematology	O
and	O
Oncology	O
.	O
He	O
was	O
promoted	O
to	O
President	O
in	O
March	O
2016	O
after	O
serving	O
as	O
Senior	O
Vice	O
President	O
of	O
Global	O
Marketing	O
since	O
July	O
2014	O
.	O
Mr.	O
Pehl	O
joined	O
Celgene	O
in	O
2006	O
as	O
General	O
Manager	O
of	O
Celgene	O
Germany	O
.	O
He	O
subsequently	O
served	O
as	O
Regional	O
Vice	O
President	O
of	O
Central	O
Europe	O
,	O
Vice	O
President	O
,	O
Head	O
of	O
Marketing	O
Europe	O
and	O
Corporate	O
Vice	O
President	O
,	O
Head	O
of	O
Global	O
Marketing	O
.	O
Before	O
coming	O
to	O
Celgene	O
,	O
he	O
spent	O
14	O
years	O
at	O
Amgen	O
,	O
Inc.	O
,	O
holding	O
various	O
positions	O
in	O
oncology	O
,	O
rheumatology	O
and	O
nephrology	O
in	O
Germany	O
and	O
for	O
Amgen	O
Europe	O
.	O
Mr.	O
Pehl	O
received	O
his	O
Diploma	O
in	O
Molecular	O
Biology	O
and	O
Biochemistry	O
from	O
Ludwig	O
Maximilian	O
University	O
of	O
Munich	O
.	O
Rupert	O
Vessey	O
,	O
MA	O
,	O
BM	O
BCh	O
,	O
FRCP	O
,	O
DPhil	O
,	O
Executive	O
Vice	O
President	O
and	O
President	O
,	O
Research	O
and	O
Early	O
Development	O
,	O
Dr.	O
Vessey	O
serves	O
as	O
President	O
of	O
Research	O
and	O
Early	O
Development	O
.	O
He	O
joined	O
Celgene	O
in	O
January	O
2015	O
as	O
Senior	O
Vice	O
President	O
,	O
Translational	O
Development	O
.	O
Before	O
joining	O
Celgene	O
,	O
Dr.	O
Vessey	O
was	O
Senior	O
Vice	O
President	O
of	O
Early	O
Development	O
and	O
Discovery	O
Sciences	O
at	O
Merck	O
.	O
During	O
his	O
ten	O
years	O
with	O
Merck	O
,	O
Dr.	O
Vessey	O
was	O
responsible	O
for	O
numerous	O
drug	O
development	O
programs	O
and	O
served	O
as	O
Senior	O
Vice	O
President	O
,	O
Early	O
Development	O
and	O
Discovery	O
Sciences	O
,	O
Senior	O
Vice	O
President	O
,	O
Respiratory	O
and	O
Immunology	O
Franchise	O
and	O
Vice	O
President	O
,	O
Drug	O
Discovery	O
and	O
Informatics	O
.	O
Prior	O
to	O
Merck	O
,	O
he	O
spent	O
five	O
years	O
at	O
GlaxoSmithKline	O
in	O
drug	O
discovery	O
,	O
experimental	O
medicine	O
and	O
early	O
clinical	O
development	O
of	O
therapeutics	O
for	O
respiratory	O
and	O
immune	O
diseases	O
.	O
Dr.	O
Vessey	O
graduated	O
from	O
Oxford	O
University	O
with	O
degrees	O
in	O
Physiological	O
Sciences	O
-LRB-	O
MA	O
-RRB-	O
,	O
Clinical	O
Medicine	O
-LRB-	O
BM	O
,	O
BCH	O
-RRB-	O
and	O
a	O
DPhil	O
-LRB-	O
PhD	O
-RRB-	O
in	O
Molecular	O
Immunology	O
.	O
He	O
is	O
an	O
elected	O
Fellow	O
of	O
the	O
Royal	O
College	O
of	O
Physicians	O
.	O
Gerald	O
F.	O
Masoudi	O
,	O
Executive	O
Vice	O
President	O
,	O
General	O
Counsel	O
and	O
Corporate	O
Secretary	O
,	O
Mr.	O
Masoudi	O
serves	O
as	O
Executive	O
Vice	O
President	O
,	O
General	O
Counsel	O
and	O
Corporate	O
Secretary	O
,	O
.	O
Mr.	O
Masoudi	O
joined	O
Celgene	O
in	O
April	O
2015	O
from	O
Covington	O
&	O
Burling	O
LLP	O
,	O
a	O
leading	O
international	O
law	O
firm	O
,	O
where	O
he	O
was	O
a	O
partner	O
and	O
served	O
as	O
co-chair	O
of	O
the	O
Food	O
and	O
Drug	O
practice	O
group	O
.	O
At	O
Covington	O
,	O
he	O
advised	O
multinational	O
companies	O
and	O
trade	O
associations	O
on	O
significant	O
litigation	O
,	O
enforcement	O
,	O
regulatory	O
and	O
public	O
policy	O
matters	O
.	O
Before	O
joining	O
Covington	O
,	O
Mr.	O
Masoudi	O
served	O
as	O
Chief	O
Counsel	O
of	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
-LRB-	O
FDA	O
-RRB-	O
.	O
Before	O
joining	O
the	O
FDA	O
as	O
Chief	O
Counsel	O
,	O
Mr.	O
Masoudi	O
served	O
as	O
Deputy	O
Assistant	O
Attorney	O
General	O
for	O
international	O
,	O
policy	O
and	O
appellate	O
matters	O
in	O
the	O
Antitrust	O
Division	O
of	O
the	O
U.S.	O
Department	O
of	O
Justice	O
.	O
Before	O
his	O
government	O
service	O
,	O
Mr.	O
Masoudi	O
was	O
a	O
trial	O
and	O
litigation	O
partner	O
with	O
the	O
law	O
firm	O
Kirkland	O
&	O
Ellis	O
.	O
Immediately	O
following	O
his	O
graduation	O
from	O
law	O
school	O
,	O
he	O
clerked	O
for	O
Judge	O
Frank	O
H.	O
Easterbrook	O
of	O
the	O
U.S.	O
Court	O
of	O
Appeals	O
for	O
the	O
Seventh	O
Circuit	O
.	O
Mr.	O
Masoudi	O
received	O
his	O
J.D.	O
from	O
The	O
University	O
of	O
Chicago	O
Law	O
School	O
,	O
graduating	O
with	O
high	O
honors	O
and	O
serving	O
on	O
the	O
editorial	O
board	O
of	O
the	O
Law	O
Review	O
.	O
He	O
received	O
his	O
B.A.	O
in	O
economics	O
from	O
Amherst	O
College	O
,	O
Phi	O
Beta	O
Kappa	O
.	O
About	O
Our	O
Story	O
Awards	O
&	O
Recognition	O
History	O
Values	O
Our	O
Values	O
Our	O
Behaviors	O
Our	O
Community	O
Our	O
Purpose	O
Employees	O
Leadership	O
Senior	O
Management	O
Board	O
of	O
Directors	O
and	O
Committees	O
Compliance	O
Code	O
of	O
Business	O
Conduct	O
and	O
Ethics	O
Sunshine	O
Act	O
FAQ	O
CA	O
Declaration	O
of	O
Compliance	O
Vermont	O
Prescriber	O
Information	O
Diversity	O
Global	O
Office	O
Network	O
Therapies	O
Anti-counterfeiting	O
Research	O
&	O
Development	O
Pipeline	O
Medical	O
Innovation	O
IMiDs	O
Anti-inflammatory	O
Compounds	O
Kinase	O
Inhibitors	O
R&D	O
Locations	O
CITRE	O
Celgene	O
Avilomics	O
Research	O
Celgene	O
Cellular	O
Therapeutics	O
Cell	O
Therapy	O
Organ	O
&	O
Tissue	O
Therapeutics	O
Selected	O
CCT	O
Publications	O
Drug	O
Discovery	O
&	O
Alliance	O
Development	O
Clinical	O
Trials	O
Celgene-sponsored	O
Trials	O
Investigator-initiated	O
Trials	O
Clinical	O
Trials	O
Data	O
Sharing	O
Celgene	O
Medical	O
Affairs	O
Educational	O
Grant	O
Requests	O
Areas	O
of	O
Focus	O
Grant	O
Application	O
Requirements	O
Budget	O
Guidelines	O
Grant	O
Application	O
Deadlines	O
Request	O
for	O
Proposal	O
Change	O
of	O
Scope	O
Budget	O
Reconciliation	O
&	O
Evaluation	O
Outcomes	O
Help	O
Resources	O
Celgene	O
Medical	O
Information	O
Medical	O
Information	O
Request	O
Form	O
Research	O
Oncology	O
lenalidomide/Revlimid	O
®	O
,	O
apremilast/Otezla	O
®	O
,	O
Purposes	O
of	O
Posting	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
,	O
,	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
,	O
Responsibility	O
Patients	O
&	O
Communities	O
Celgene	O
Support	O
Sponsorships	O
&	O
Donations	O
Charitable	O
&	O
Philanthropic	O
Contributions	O
Light	O
the	O
Night	O
Pancreatic	O
Cancer	O
Action	O
Network	O
PurpleStride	O
®	O
Innovation	O
Impact	O
Awards	O
2016	O
Awards	O
Overview	O
2015	O
Innovation	O
Impact	O
Winners	O
2014	O
Innovation	O
Impact	O
Winners	O
2013	O
Innovation	O
Impact	O
Winners	O
Access	O
to	O
Medicine	O
Principles	O
for	O
Pricing	O
of	O
Innovative	O
Medicines	O
European	O
Patient	O
Group	O
Support	O
EFPIA	O
Spend	O
Transparency	O
Disclosure	O
Commitment	O
to	O
Safety	O
Patient	O
Safety	O
Employee	O
Safety	O
Governance	O
Sustainability	O
Governance	O
Compliance	O
&	O
Ethics	O
Reportable	O
Allegations	O
Filing	O
an	O
Online	O
Report	O
Country	O
Access	O
Codes	O
Public	O
Policy	O
Engagement	O
Association	O
Memberships	O
Supply	O
Chain	O
Global	O
Health	O
Environment	O
&	O
Sustainability	O
Environmental	O
Management	O
Sustainable	O
Facilities	O
Awards	O
&	O
Designations	O
CDP	O
-LRB-	O
Carbon	O
Disclosure	O
Project	O
-RRB-	O
Patient	O
Advocacy	O
Sponsorship	O
&	O
Donation	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
Application	O
Requirements	O
2016	O
Reaching	O
the	O
Unreached	O
New	O
Features	O
in	O
2016	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
Judges	O
FAQ	O
New	O
Features	O
In	O
2015	O
!	O
2016	O
Award	O
Video	O
Tips	O
&	O
Resources	O
Timeline	O
&	O
Process	O
Contact	O
Us	O
Application	O
2015	O
Patient	O
Voice	O
``	O
GAPS	O
''	O
2015	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2015	O
Award	O
Judges	O
2014	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2014	O
Award	O
Judges	O
2013	O
Award	O
Criteria	O
&	O
Rules	O
2013	O
Award	O
Judges	O
Patient	O
Group	O
Support	O
--	O
Pan-European	O
Patient	O
Group	O
Support	O
--	O
Austria	O
Patient	O
Group	O
Support	O
--	O
Belgium	O
Patient	O
Group	O
Support	O
--	O
Bosnia	O
Patient	O
Group	O
Support	O
--	O
Croatia	O
Patient	O
Group	O
Support	O
--	O
Cyprus	O
Patient	O
Group	O
Support	O
--	O
Czech	O
Republic	O
Patient	O
Group	O
Support	O
--	O
Denmark	O
Patient	O
Group	O
Support	O
--	O
Estonia	O
Patient	O
Group	O
Support	O
--	O
Finland	O
Patient	O
Group	O
Support	O
--	O
France	O
Patient	O
Group	O
Support	O
--	O
Germany	O
Patient	O
Group	O
Support	O
--	O
Greece	O
Patient	O
Group	O
Support	O
--	O
Hungary	O
Patient	O
Group	O
Support	O
--	O
Israel	O
Patient	O
Group	O
Support	O
--	O
Italy	O
Patient	O
Group	O
Support	O
--	O
Latvia	O
Patient	O
Group	O
Support	O
--	O
Lithuania	O
Patient	O
Group	O
Support	O
--	O
Macedonia	O
Patient	O
Group	O
Support	O
--	O
Netherlands	O
Patient	O
Group	O
Support	O
--	O
Norway	O
Patient	O
Group	O
Support	O
--	O
Poland	O
Patient	O
Group	O
Support	O
--	O
Portugal	O
Patient	O
Group	O
Support	O
--	O
Romania	O
Patient	O
Group	O
Support	O
--	O
Russia	O
Patient	O
Group	O
Support	O
--	O
Serbia	O
Patient	O
Group	O
Support	O
--	O
Slovakia	O
Patient	O
Group	O
Support	O
--	O
Slovenia	O
Patient	O
Group	O
Support	O
--	O
Spain	O
Patient	O
Group	O
Support	O
--	O
Sweden	O
Patient	O
Group	O
Support	O
--	O
Switzerland	O
Patient	O
Group	O
Support	O
--	O
Turkey	O
EFPIA	O
--	O
Austria	O
EFPIA	O
--	O
Bulgaria	O
EFPIA	O
--	O
Croatia	O
EFPIA	O
--	O
Cyprus	O
EFPIA	O
--	O
Czech	O
Republic	O
EFPIA	O
--	O
Estonia	O
EFPIA	O
--	O
Greece	O
EFPIA	O
--	O
Hungary	O
EFPIA	O
--	O
Latvia	O
EFPIA	O
--	O
Lithuania	O
EFPIA	O
--	O
Poland	O
EFPIA	O
--	O
Romania	O
EFPIA	O
--	O
Serbia	O
EFPIA	O
--	O
Slovakia	O
EFPIA	O
--	O
Slovenia	O
EFPIA	O
--	O
Ukraine	O
Newsroom	O
Media	O
Contacts	O
Multimedia	O
Library	O
Press	O
Releases	O
Events	O
Patients	O
Celgene	O
Patient	O
Support	O
Online	O
Patient	O
Resources	O
REMS	O
--	O
Pharmacy	O
Network	O
Glossary	O
Medical	O
Professionals	O
Partnerships	O
Business	O
Development	O
Partnerships	O
Global	O
Health	O
Partnerships	O
Advocacy	O
Partnerships	O
Suppliers	O
Suppliers	O
Form	O
Investors	O
Careers	O
Contact	O
Us	O
Contact	O
Us	O
--	O
Mobile	O
Shared	O
Services	O
Value	O
of	O
Medical	O
Innovation	O
PhRMA	O
Resources	O
Access	O
Innovation	O
Value	O
Terms	O
of	O
Use	O
Privacy	O
Policy	O
Site	O
Map	O
Community	O
Guidelines	O
Standing	O
in	O
the	O
GaaP	O
Facebook	O
Community	O
Guidelines	O
Celgene	O
Facebook	O
Community	O
Guidelines	O
The	O
Celgene	O
REMS	O
mobile	O
application	O
is	O
temporarily	O
unavailable	O
Celgene	O
Clinical	O
Trials	O
Information	O
Patients	O
'	O
Partners	O
--	O
ASH	O
2015	O
Patients	O
'	O
Partners	O
--	O
ASCO	O
2016	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
One	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
Two	O
Patients	O
'	O
Partners	O
Webinar	O
Registration	O
Publications	O
Instagram	O
Millefeuille	O
Movie	O
Community	O
Guidelines	O
Research	O
Oncology	O
About	O
Our	O
Story	O
Awards	O
&	O
Recognition	O
History	O
Values	O
Our	O
Values	O
Our	O
Behaviors	O
Our	O
Community	O
Our	O
Purpose	O
Employees	O
Leadership	O
Senior	O
Management	O
Board	O
of	O
Directors	O
and	O
Committees	O
Compliance	O
Code	O
of	O
Business	O
Conduct	O
and	O
Ethics	O
Sunshine	O
Act	O
FAQ	O
,	O
CA	O
Declaration	O
of	O
Compliance	O
Vermont	O
Prescriber	O
Information	O
Diversity	O
Global	O
Office	O
Network	O
Therapies	O
Anti-counterfeiting	O
Research	O
&	O
Development	O
Pipeline	O
Medical	O
Innovation	O
IMiDs	O
Anti-inflammatory	O
Compounds	O
Kinase	O
Inhibitors	O
R&D	O
Locations	O
CITRE	O
Celgene	O
Avilomics	O
Research	O
Celgene	O
Cellular	O
Therapeutics	O
Cell	O
Therapy	O
Organ	O
&	O
Tissue	O
Therapeutics	O
Selected	O
CCT	O
Publications	O
Drug	O
Discovery	O
&	O
Alliance	O
Development	O
Clinical	O
Trials	O
Celgene-sponsored	O
Trials	O
Investigator-initiated	O
Trials	O
Clinical	O
Trials	O
Data	O
Sharing	O
Celgene	O
Medical	O
Affairs	O
Educational	O
Grant	O
Requests	O
Areas	O
of	O
Focus	O
Grant	O
Application	O
,	O
Requirements	O
Budget	O
Guidelines	O
Grant	O
Application	O
,	O
Deadlines	O
Request	O
for	O
Proposal	O
Change	O
of	O
Scope	O
Budget	O
Reconciliation	O
&	O
Evaluation	O
Outcomes	O
Help	O
Resources	O
Celgene	O
Medical	O
Information	O
Medical	O
Information	O
Request	O
Form	O
Research	O
Oncology	O
lenalidomide/Revlimid	O
®	O
apremilast/Otezla	O
®	O
Purposes	O
of	O
Posting	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Responsibility	O
Patients	O
&	O
Communities	O
Celgene	O
Support	O
Sponsorships	O
&	O
Donations	O
Charitable	O
&	O
Philanthropic	O
Contributions	O
Light	O
the	O
Night	O
Pancreatic	O
Cancer	O
Action	O
Network	O
PurpleStride	O
®	O
Innovation	O
Impact	O
Awards	O
2016	O
Awards	O
Overview	O
2015	O
Innovation	O
Impact	O
Winners	O
2014	O
Innovation	O
Impact	O
Winners	O
2013	O
Innovation	O
Impact	O
Winners	O
Access	O
to	O
Medicine	O
Principles	O
for	O
Pricing	O
of	O
Innovative	O
Medicines	O
European	O
Patient	O
Group	O
Support	O
EFPIA	O
Spend	O
Transparency	O
Disclosure	O
Commitment	O
to	O
Safety	O
Patient	O
Safety	O
Employee	O
Safety	O
Governance	O
Sustainability	O
Governance	O
Compliance	O
&	O
Ethics	O
Reportable	O
Allegations	O
Filing	O
an	O
Online	O
Report	O
Country	O
Access	O
Codes	O
Public	O
Policy	O
Engagement	O
Association	O
Memberships	O
Supply	O
Chain	O
Global	O
Health	O
Environment	O
&	O
Sustainability	O
Environmental	O
Management	O
Sustainable	O
Facilities	O
Awards	O
&	O
Designations	O
CDP	O
-LRB-	O
Carbon	O
Disclosure	O
Project	O
-RRB-	O
Patient	O
Advocacy	O
Sponsorship	O
&	O
Donation	O
FAQ	O
,	O
,	O
Civic	O
and	O
Philanthropic	O
Contributions	O
FAQ	O
,	O
,	O
Civic	O
and	O
Philanthropic	O
Contributions	O
Application	O
,	O
Requirements	O
,	O
2016	O
Reaching	O
the	O
Unreached	O
,	O
New	O
Features	O
in	O
2016	O
,	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
,	O
Judges	O
,	O
FAQ	O
,	O
New	O
Features	O
In	O
2015	O
!	O
,	O
2016	O
Award	O
Video	O
Tips	O
&	O
Resources	O
,	O
Timeline	O
&	O
Process	O
,	O
Contact	O
Us	O
,	O
Application	O
,	O
2015	O
Patient	O
Voice	O
``	O
GAPS	O
''	O
,	O
2015	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
,	O
,	O
2015	O
Award	O
Judges	O
,	O
,	O
2014	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
,	O
,	O
2014	O
Award	O
Judges	O
,	O
,	O
2013	O
Award	O
Criteria	O
&	O
Rules	O
,	O
2013	O
Award	O
Judges	O
,	O
,	O
Patient	O
Group	O
Support	O
--	O
Pan-European	O
,	O
Patient	O
Group	O
Support	O
--	O
Austria	O
,	O
Patient	O
Group	O
Support	O
--	O
Belgium	O
,	O
Patient	O
Group	O
Support	O
--	O
Bosnia	O
,	O
Patient	O
Group	O
Support	O
--	O
Croatia	O
,	O
Patient	O
Group	O
Support	O
--	O
Cyprus	O
,	O
Patient	O
Group	O
Support	O
--	O
Czech	O
Republic	O
,	O
Patient	O
Group	O
Support	O
--	O
Denmark	O
,	O
Patient	O
Group	O
Support	O
--	O
Estonia	O
,	O
Patient	O
Group	O
Support	O
--	O
Finland	O
,	O
Patient	O
Group	O
Support	O
--	O
France	O
,	O
Patient	O
Group	O
Support	O
--	O
Germany	O
,	O
Patient	O
Group	O
Support	O
--	O
Greece	O
,	O
Patient	O
Group	O
Support	O
--	O
Hungary	O
,	O
Patient	O
Group	O
Support	O
--	O
Israel	O
,	O
Patient	O
Group	O
Support	O
--	O
Italy	O
,	O
Patient	O
Group	O
Support	O
--	O
Latvia	O
,	O
Patient	O
Group	O
Support	O
--	O
Lithuania	O
,	O
Patient	O
Group	O
Support	O
--	O
Macedonia	O
,	O
Patient	O
Group	O
Support	O
--	O
Netherlands	O
,	O
Patient	O
Group	O
Support	O
--	O
Norway	O
,	O
Patient	O
Group	O
Support	O
--	O
Poland	O
,	O
Patient	O
Group	O
Support	O
--	O
Portugal	O
,	O
Patient	O
Group	O
Support	O
--	O
Romania	O
,	O
Patient	O
Group	O
Support	O
--	O
Russia	O
,	O
Patient	O
Group	O
Support	O
--	O
Serbia	O
,	O
Patient	O
Group	O
Support	O
--	O
Slovakia	O
,	O
Patient	O
Group	O
Support	O
--	O
Slovenia	O
,	O
Patient	O
Group	O
Support	O
--	O
Spain	O
,	O
Patient	O
Group	O
Support	O
--	O
Sweden	O
,	O
Patient	O
Group	O
Support	O
--	O
Switzerland	O
,	O
Patient	O
Group	O
Support	O
--	O
Turkey	O
,	O
EFPIA	O
--	O
Austria	O
,	O
EFPIA	O
--	O
Bulgaria	O
,	O
EFPIA	O
--	O
Croatia	O
,	O
EFPIA	O
--	O
Cyprus	O
,	O
EFPIA	O
--	O
Czech	O
Republic	O
,	O
EFPIA	O
--	O
Estonia	O
,	O
EFPIA	O
--	O
Greece	O
,	O
EFPIA	O
--	O
Hungary	O
,	O
EFPIA	O
--	O
Latvia	O
,	O
EFPIA	O
--	O
Lithuania	O
,	O
EFPIA	O
--	O
Poland	O
,	O
EFPIA	O
--	O
Romania	O
,	O
EFPIA	O
--	O
Serbia	O
,	O
EFPIA	O
--	O
Slovakia	O
,	O
EFPIA	O
--	O
Slovenia	O
,	O
EFPIA	O
--	O
Ukraine	O
,	O
Newsroom	O
Media	O
Contacts	O
Multimedia	O
Library	O
Press	O
Releases	O
Events	O
Patients	O
Celgene	O
Patient	O
Support	O
Online	O
Patient	O
Resources	O
REMS	O
--	O
Pharmacy	O
Network	O
Glossary	O
Medical	O
Professionals	O
Partnerships	O
Business	O
Development	O
Partnerships	O
Global	O
Health	O
Partnerships	O
Advocacy	O
Partnerships	O
Suppliers	O
Suppliers	O
Form	O
Investors	O
Careers	O
Contact	O
Us	O
,	O
Contact	O
Us	O
,	O
--	O
Mobile	O
Shared	O
Services	O
Value	O
of	O
Medical	O
Innovation	O
PhRMA	O
Resources	O
Access	O
Innovation	O
Value	O
Terms	O
of	O
Use	O
Privacy	O
Policy	O
Site	O
Map	O
Community	O
Guidelines	O
Standing	O
in	O
the	O
GaaP	O
Facebook	O
Community	O
Guidelines	O
Celgene	O
Facebook	O
Community	O
Guidelines	O
The	O
Celgene	O
REMS	O
mobile	O
application	O
is	O
temporarily	O
unavailable	O
Celgene	O
Clinical	O
Trials	O
Information	O
Patients	O
'	O
Partners	O
--	O
ASH	O
2015	O
Patients	O
'	O
Partners	O
--	O
ASCO	O
2016	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
One	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
Two	O
Patients	O
'	O
Partners	O
Webinar	O
Registration	O
Publications	O
Instagram	O
Millefeuille	O
Movie	O
Community	O
Guidelines	O
Research	O
Oncology	O
About	O
Our	O
Story	O
Awards	O
&	O
Recognition	O
History	O
Values	O
Our	O
Values	O
Our	O
Behaviors	O
Our	O
Community	O
Our	O
Purpose	O
Employees	O
Leadership	O
Senior	O
Management	O
Board	O
of	O
Directors	O
and	O
Committees	O
Compliance	O
Code	O
of	O
Business	O
Conduct	O
and	O
Ethics	O
Sunshine	O
Act	O
FAQ	O
CA	O
Declaration	O
of	O
Compliance	O
Vermont	O
Prescriber	O
Information	O
Diversity	O
Global	O
Office	O
Network	O
Therapies	O
Anti-counterfeiting	O
Research	O
&	O
Development	O
Pipeline	O
Medical	O
Innovation	O
IMiDs	O
Anti-inflammatory	O
Compounds	O
Kinase	O
Inhibitors	O
R&D	O
Locations	O
CITRE	O
Celgene	O
Avilomics	O
Research	O
Celgene	O
Cellular	O
Therapeutics	O
Cell	O
Therapy	O
Organ	O
&	O
Tissue	O
Therapeutics	O
Selected	O
CCT	O
Publications	O
Drug	O
Discovery	O
&	O
Alliance	O
Development	O
Clinical	O
Trials	O
Celgene-sponsored	O
Trials	O
Investigator-initiated	O
Trials	O
Clinical	O
Trials	O
Data	O
Sharing	O
Celgene	O
Medical	O
Affairs	O
Educational	O
Grant	O
Requests	O
Areas	O
of	O
Focus	O
Grant	O
Application	O
Requirements	O
Budget	O
Guidelines	O
Grant	O
Application	O
Deadlines	O
Request	O
for	O
Proposal	O
Change	O
of	O
Scope	O
Budget	O
Reconciliation	O
&	O
Evaluation	O
Outcomes	O
Help	O
Resources	O
Celgene	O
Medical	O
Information	O
Medical	O
Information	O
Request	O
Form	O
Research	O
Oncology	O
lenalidomide/Revlimid	O
®	O
apremilast/Otezla	O
®	O
Purposes	O
of	O
Posting	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Responsibility	O
Patients	O
&	O
Communities	O
Celgene	O
Support	O
Sponsorships	O
&	O
Donations	O
Charitable	O
&	O
Philanthropic	O
Contributions	O
Light	O
the	O
Night	O
Pancreatic	O
Cancer	O
Action	O
Network	O
PurpleStride	O
®	O
Innovation	O
Impact	O
Awards	O
2016	O
Awards	O
Overview	O
2015	O
Innovation	O
Impact	O
Winners	O
2014	O
Innovation	O
Impact	O
Winners	O
2013	O
Innovation	O
Impact	O
Winners	O
Access	O
to	O
Medicine	O
Principles	O
for	O
Pricing	O
of	O
Innovative	O
Medicines	O
European	O
Patient	O
Group	O
Support	O
EFPIA	O
Spend	O
Transparency	O
Disclosure	O
Commitment	O
to	O
Safety	O
Patient	O
Safety	O
Employee	O
Safety	O
Governance	O
Sustainability	O
Governance	O
Compliance	O
&	O
Ethics	O
Reportable	O
Allegations	O
Filing	O
an	O
Online	O
Report	O
Country	O
Access	O
Codes	O
Public	O
Policy	O
Engagement	O
Association	O
Memberships	O
Supply	O
Chain	O
Global	O
Health	O
Environment	O
&	O
Sustainability	O
Environmental	O
Management	O
Sustainable	O
Facilities	O
Awards	O
&	O
Designations	O
CDP	O
-LRB-	O
Carbon	O
Disclosure	O
Project	O
-RRB-	O
Patient	O
Advocacy	O
Sponsorship	O
&	O
Donation	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
Application	O
Requirements	O
2016	O
Reaching	O
the	O
Unreached	O
New	O
Features	O
in	O
2016	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
Judges	O
FAQ	O
New	O
Features	O
In	O
2015	O
!	O
2016	O
Award	O
Video	O
Tips	O
&	O
Resources	O
Timeline	O
&	O
Process	O
Contact	O
Us	O
Application	O
2015	O
Patient	O
Voice	O
``	O
GAPS	O
''	O
2015	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2015	O
Award	O
Judges	O
2014	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2014	O
Award	O
Judges	O
2013	O
Award	O
Criteria	O
&	O
Rules	O
2013	O
Award	O
Judges	O
Patient	O
Group	O
Support	O
--	O
Pan-European	O
Patient	O
Group	O
Support	O
--	O
Austria	O
Patient	O
Group	O
Support	O
--	O
Belgium	O
Patient	O
Group	O
Support	O
--	O
Bosnia	O
Patient	O
Group	O
Support	O
--	O
Croatia	O
Patient	O
Group	O
Support	O
--	O
Cyprus	O
Patient	O
Group	O
Support	O
--	O
Czech	O
Republic	O
Patient	O
Group	O
Support	O
--	O
Denmark	O
Patient	O
Group	O
Support	O
--	O
Estonia	O
Patient	O
Group	O
Support	O
--	O
Finland	O
Patient	O
Group	O
Support	O
--	O
France	O
Patient	O
Group	O
Support	O
--	O
Germany	O
Patient	O
Group	O
Support	O
--	O
Greece	O
Patient	O
Group	O
Support	O
--	O
Hungary	O
Patient	O
Group	O
Support	O
--	O
Israel	O
Patient	O
Group	O
Support	O
--	O
Italy	O
Patient	O
Group	O
Support	O
--	O
Latvia	O
Patient	O
Group	O
Support	O
--	O
Lithuania	O
Patient	O
Group	O
Support	O
--	O
Macedonia	O
Patient	O
Group	O
Support	O
--	O
Netherlands	O
Patient	O
Group	O
Support	O
--	O
Norway	O
Patient	O
Group	O
Support	O
--	O
Poland	O
Patient	O
Group	O
Support	O
--	O
Portugal	O
Patient	O
Group	O
Support	O
--	O
Romania	O
Patient	O
Group	O
Support	O
--	O
Russia	O
Patient	O
Group	O
Support	O
--	O
Serbia	O
Patient	O
Group	O
Support	O
--	O
Slovakia	O
Patient	O
Group	O
Support	O
--	O
Slovenia	O
Patient	O
Group	O
Support	O
--	O
Spain	O
Patient	O
Group	O
Support	O
--	O
Sweden	O
Patient	O
Group	O
Support	O
--	O
Switzerland	O
Patient	O
Group	O
Support	O
--	O
Turkey	O
EFPIA	O
--	O
Austria	O
EFPIA	O
--	O
Bulgaria	O
EFPIA	O
--	O
Croatia	O
EFPIA	O
--	O
Cyprus	O
EFPIA	O
--	O
Czech	O
Republic	O
EFPIA	O
--	O
Estonia	O
EFPIA	O
--	O
Greece	O
EFPIA	O
--	O
Hungary	O
EFPIA	O
--	O
Latvia	O
EFPIA	O
--	O
Lithuania	O
EFPIA	O
--	O
Poland	O
EFPIA	O
--	O
Romania	O
EFPIA	O
--	O
Serbia	O
EFPIA	O
--	O
Slovakia	O
EFPIA	O
--	O
Slovenia	O
EFPIA	O
--	O
Ukraine	O
Newsroom	O
Media	O
Contacts	O
Multimedia	O
Library	O
Press	O
Releases	O
Events	O
Patients	O
Celgene	O
Patient	O
Support	O
Online	O
Patient	O
Resources	O
REMS	O
--	O
Pharmacy	O
Network	O
Glossary	O
Medical	O
Professionals	O
,	O
Partnerships	O
Business	O
Development	O
Partnerships	O
Global	O
Health	O
Partnerships	O
Advocacy	O
Partnerships	O
Suppliers	O
Suppliers	O
Form	O
Investors	O
Careers	O
Contact	O
Us	O
Contact	O
Us	O
--	O
Mobile	O
Shared	O
Services	O
Value	O
of	O
Medical	O
Innovation	O
PhRMA	O
Resources	O
Access	O
Innovation	O
Value	O
Terms	O
of	O
Use	O
Privacy	O
Policy	O
Site	O
Map	O
Community	O
Guidelines	O
Standing	O
in	O
the	O
GaaP	O
Facebook	O
Community	O
Guidelines	O
Celgene	O
Facebook	O
Community	O
Guidelines	O
The	O
Celgene	O
REMS	O
mobile	O
application	O
is	O
temporarily	O
unavailable	O
Celgene	O
Clinical	O
Trials	O
Information	O
Patients	O
'	O
Partners	O
--	O
ASH	O
2015	O
Patients	O
'	O
Partners	O
--	O
ASCO	O
2016	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
One	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
Two	O
Patients	O
'	O
Partners	O
Webinar	O
Registration	O
Publications	O
Instagram	O
Millefeuille	O
Movie	O
Community	O
Guidelines	O
Research	O
Oncology	O
About	O
Our	O
Story	O
Awards	O
&	O
Recognition	O
History	O
Values	O
Our	O
Values	O
Our	O
Behaviors	O
Our	O
Community	O
Our	O
Purpose	O
Employees	O
Leadership	O
Senior	O
Management	O
Board	O
of	O
Directors	O
and	O
Committees	O
Compliance	O
Code	O
of	O
Business	O
Conduct	O
and	O
Ethics	O
Sunshine	O
Act	O
FAQ	O
CA	O
Declaration	O
of	O
Compliance	O
Vermont	O
Prescriber	O
Information	O
Diversity	O
Global	O
Office	O
Network	O
Therapies	O
Anti-counterfeiting	O
Research	O
&	O
Development	O
Pipeline	O
Medical	O
Innovation	O
IMiDs	O
Anti-inflammatory	O
Compounds	O
Kinase	O
Inhibitors	O
R&D	O
Locations	O
CITRE	O
Celgene	O
Avilomics	O
Research	O
Celgene	O
Cellular	O
Therapeutics	O
Cell	O
Therapy	O
Organ	O
&	O
Tissue	O
Therapeutics	O
Selected	O
CCT	O
Publications	O
Drug	O
Discovery	O
&	O
Alliance	O
Development	O
Clinical	O
Trials	O
Celgene-sponsored	O
Trials	O
Investigator-initiated	O
Trials	O
Clinical	O
Trials	O
Data	O
Sharing	O
Celgene	O
Medical	O
Affairs	O
Educational	O
Grant	O
Requests	O
Areas	O
of	O
Focus	O
Grant	O
Application	O
Requirements	O
Budget	O
Guidelines	O
Grant	O
Application	O
Deadlines	O
Request	O
for	O
Proposal	O
Change	O
of	O
Scope	O
Budget	O
Reconciliation	O
&	O
Evaluation	O
Outcomes	O
Help	O
Resources	O
Celgene	O
Medical	O
Information	O
Medical	O
Information	O
Request	O
Form	O
Research	O
Oncology	O
lenalidomide/Revlimid	O
®	O
apremilast/Otezla	O
®	O
Purposes	O
of	O
Posting	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Responsibility	O
Patients	O
&	O
Communities	O
Celgene	O
Support	O
Sponsorships	O
&	O
Donations	O
Charitable	O
&	O
Philanthropic	O
Contributions	O
Light	O
the	O
Night	O
Pancreatic	O
Cancer	O
Action	O
Network	O
PurpleStride	O
®	O
Innovation	O
Impact	O
Awards	O
2016	O
Awards	O
Overview	O
2015	O
Innovation	O
Impact	O
Winners	O
2014	O
Innovation	O
Impact	O
Winners	O
2013	O
Innovation	O
Impact	O
Winners	O
Access	O
to	O
Medicine	O
Principles	O
for	O
Pricing	O
of	O
Innovative	O
Medicines	O
European	O
Patient	O
Group	O
Support	O
EFPIA	O
Spend	O
Transparency	O
Disclosure	O
Commitment	O
to	O
Safety	O
Patient	O
Safety	O
Employee	O
Safety	O
Governance	O
Sustainability	O
Governance	O
Compliance	O
&	O
Ethics	O
Reportable	O
Allegations	O
Filing	O
an	O
Online	O
Report	O
Country	O
Access	O
Codes	O
Public	O
Policy	O
Engagement	O
Association	O
Memberships	O
Supply	O
Chain	O
Global	O
Health	O
Environment	O
&	O
Sustainability	O
Environmental	O
Management	O
Sustainable	O
Facilities	O
Awards	O
&	O
Designations	O
CDP	O
-LRB-	O
Carbon	O
Disclosure	O
Project	O
-RRB-	O
Patient	O
Advocacy	O
Sponsorship	O
&	O
Donation	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
Application	O
Requirements	O
2016	O
Reaching	O
the	O
Unreached	O
New	O
Features	O
in	O
2016	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
Judges	O
FAQ	O
New	O
Features	O
In	O
2015	O
!	O
2016	O
Award	O
Video	O
Tips	O
&	O
Resources	O
Timeline	O
&	O
Process	O
Contact	O
Us	O
,	O
Application	O
2015	O
Patient	O
Voice	O
``	O
GAPS	O
''	O
2015	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2015	O
Award	O
Judges	O
2014	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2014	O
Award	O
Judges	O
2013	O
Award	O
Criteria	O
&	O
Rules	O
2013	O
Award	O
Judges	O
Patient	O
Group	O
Support	O
--	O
Pan-European	O
Patient	O
Group	O
Support	O
--	O
Austria	O
Patient	O
Group	O
Support	O
--	O
Belgium	O
Patient	O
Group	O
Support	O
--	O
Bosnia	O
Patient	O
Group	O
Support	O
--	O
Croatia	O
Patient	O
Group	O
Support	O
--	O
Cyprus	O
Patient	O
Group	O
Support	O
--	O
Czech	O
Republic	O
Patient	O
Group	O
Support	O
--	O
Denmark	O
Patient	O
Group	O
Support	O
--	O
Estonia	O
Patient	O
Group	O
Support	O
--	O
Finland	O
Patient	O
Group	O
Support	O
--	O
France	O
Patient	O
Group	O
Support	O
--	O
Germany	O
Patient	O
Group	O
Support	O
--	O
Greece	O
Patient	O
Group	O
Support	O
--	O
Hungary	O
Patient	O
Group	O
Support	O
--	O
Israel	O
Patient	O
Group	O
Support	O
--	O
Italy	O
Patient	O
Group	O
Support	O
--	O
Latvia	O
Patient	O
Group	O
Support	O
--	O
Lithuania	O
Patient	O
Group	O
Support	O
--	O
Macedonia	O
Patient	O
Group	O
Support	O
--	O
Netherlands	O
Patient	O
Group	O
Support	O
--	O
Norway	O
Patient	O
Group	O
Support	O
--	O
Poland	O
Patient	O
Group	O
Support	O
--	O
Portugal	O
Patient	O
Group	O
Support	O
--	O
Romania	O
Patient	O
Group	O
Support	O
--	O
Russia	O
Patient	O
Group	O
Support	O
--	O
Serbia	O
Patient	O
Group	O
Support	O
--	O
Slovakia	O
Patient	O
Group	O
Support	O
--	O
Slovenia	O
Patient	O
Group	O
Support	O
--	O
Spain	O
Patient	O
Group	O
Support	O
--	O
Sweden	O
Patient	O
Group	O
Support	O
--	O
Switzerland	O
Patient	O
Group	O
Support	O
--	O
Turkey	O
EFPIA	O
--	O
Austria	O
EFPIA	O
--	O
Bulgaria	O
EFPIA	O
--	O
Croatia	O
EFPIA	O
--	O
Cyprus	O
EFPIA	O
--	O
Czech	O
Republic	O
EFPIA	O
--	O
Estonia	O
EFPIA	O
--	O
Greece	O
EFPIA	O
--	O
Hungary	O
EFPIA	O
--	O
Latvia	O
EFPIA	O
--	O
Lithuania	O
EFPIA	O
--	O
Poland	O
EFPIA	O
--	O
Romania	O
EFPIA	O
--	O
Serbia	O
EFPIA	O
--	O
Slovakia	O
EFPIA	O
--	O
Slovenia	O
EFPIA	O
--	O
Ukraine	O
Newsroom	O
Media	O
Contacts	O
Multimedia	O
Library	O
Press	O
Releases	O
Events	O
Patients	O
Celgene	O
Patient	O
Support	O
Online	O
Patient	O
Resources	O
REMS	O
--	O
Pharmacy	O
Network	O
Glossary	O
Medical	O
Professionals	O
Partnerships	O
Business	O
Development	O
Partnerships	O
Global	O
Health	O
Partnerships	O
Advocacy	O
Partnerships	O
Suppliers	O
Suppliers	O
Form	O
Investors	O
,	O
Careers	O
,	O
Contact	O
Us	O
,	O
Contact	O
Us	O
,	O
--	O
Mobile	O
Shared	O
Services	O
Value	O
of	O
Medical	O
Innovation	O
PhRMA	O
Resources	O
Access	O
Innovation	O
Value	O
Terms	O
of	O
Use	O
Privacy	O
Policy	O
Site	O
Map	O
Community	O
Guidelines	O
Standing	O
in	O
the	O
GaaP	O
Facebook	O
Community	O
Guidelines	O
Celgene	O
Facebook	O
Community	O
Guidelines	O
The	O
Celgene	O
REMS	O
mobile	O
application	O
is	O
temporarily	O
unavailable	O
Celgene	O
Clinical	O
Trials	O
Information	O
Patients	O
'	O
Partners	O
--	O
ASH	O
2015	O
Patients	O
'	O
Partners	O
--	O
ASCO	O
2016	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
One	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
Two	O
Patients	O
'	O
Partners	O
Webinar	O
Registration	O
Publications	O
Instagram	O
Millefeuille	O
Movie	O
Community	O
Guidelines	O
Research	O
Oncology	O
About	O
Our	O
Story	O
Awards	O
&	O
Recognition	O
History	O
Values	O
Our	O
Values	O
Our	O
Behaviors	O
Our	O
Community	O
Our	O
Purpose	O
Employees	O
Leadership	O
Senior	O
Management	O
Board	O
of	O
Directors	O
and	O
Committees	O
Compliance	O
Code	O
of	O
Business	O
Conduct	O
and	O
Ethics	O
Sunshine	O
Act	O
FAQ	O
CA	O
Declaration	O
of	O
Compliance	O
Vermont	O
Prescriber	O
Information	O
Diversity	O
Global	O
Office	O
Network	O
Therapies	O
Anti-counterfeiting	O
Research	O
&	O
Development	O
Pipeline	O
Medical	O
Innovation	O
IMiDs	O
Anti-inflammatory	O
Compounds	O
Kinase	O
Inhibitors	O
R&D	O
Locations	O
CITRE	O
Celgene	O
Avilomics	O
Research	O
Celgene	O
Cellular	O
Therapeutics	O
Cell	O
Therapy	O
Organ	O
&	O
Tissue	O
Therapeutics	O
Selected	O
CCT	O
Publications	O
,	O
Drug	O
Discovery	O
&	O
Alliance	O
Development	O
Clinical	O
Trials	O
Celgene-sponsored	O
Trials	O
Investigator-initiated	O
Trials	O
Clinical	O
Trials	O
Data	O
Sharing	O
Celgene	O
Medical	O
Affairs	O
Educational	O
Grant	O
Requests	O
Areas	O
of	O
Focus	O
Grant	O
Application	O
Requirements	O
Budget	O
Guidelines	O
Grant	O
Application	O
Deadlines	O
Request	O
for	O
Proposal	O
Change	O
of	O
Scope	O
Budget	O
Reconciliation	O
&	O
Evaluation	O
Outcomes	O
Help	O
Resources	O
Celgene	O
Medical	O
Information	O
Medical	O
Information	O
Request	O
Form	O
Research	O
Oncology	O
,	O
lenalidomide/Revlimid	O
®	O
apremilast/Otezla	O
®	O
Purposes	O
of	O
Posting	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Clinical	O
Study	O
Report	O
-LRB-	O
CSR	O
-RRB-	O
Synopses	O
Responsibility	O
Patients	O
&	O
Communities	O
Celgene	O
Support	O
Sponsorships	O
&	O
Donations	O
Charitable	O
&	O
Philanthropic	O
Contributions	O
Light	O
the	O
Night	O
Pancreatic	O
Cancer	O
Action	O
Network	O
PurpleStride	O
®	O
Innovation	O
Impact	O
Awards	O
2016	O
Awards	O
Overview	O
2015	O
Innovation	O
Impact	O
Winners	O
2014	O
Innovation	O
Impact	O
Winners	O
2013	O
Innovation	O
Impact	O
Winners	O
Access	O
to	O
Medicine	O
Principles	O
for	O
Pricing	O
of	O
Innovative	O
Medicines	O
European	O
Patient	O
Group	O
Support	O
EFPIA	O
Spend	O
Transparency	O
Disclosure	O
Commitment	O
to	O
Safety	O
Patient	O
Safety	O
Employee	O
Safety	O
Governance	O
Sustainability	O
Governance	O
Compliance	O
&	O
Ethics	O
Reportable	O
Allegations	O
Filing	O
an	O
Online	O
Report	O
Country	O
Access	O
Codes	O
Public	O
Policy	O
Engagement	O
Association	O
Memberships	O
Supply	O
Chain	O
Global	O
Health	O
Environment	O
&	O
Sustainability	O
Environmental	O
Management	O
Sustainable	O
Facilities	O
Awards	O
&	O
Designations	O
CDP	O
-LRB-	O
Carbon	O
Disclosure	O
Project	O
-RRB-	O
Patient	O
Advocacy	O
Sponsorship	O
&	O
Donation	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
FAQ	O
Civic	O
and	O
Philanthropic	O
Contributions	O
Application	O
Requirements	O
2016	O
Reaching	O
the	O
Unreached	O
New	O
Features	O
in	O
2016	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
Judges	O
FAQ	O
New	O
Features	O
In	O
2015	O
!	O
2016	O
Award	O
Video	O
Tips	O
&	O
Resources	O
Timeline	O
&	O
Process	O
Contact	O
Us	O
Application	O
2015	O
Patient	O
Voice	O
``	O
GAPS	O
''	O
2015	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2015	O
Award	O
Judges	O
2014	O
Criteria	O
,	O
Scope	O
&	O
Restrictions	O
2014	O
Award	O
Judges	O
2013	O
Award	O
Criteria	O
&	O
Rules	O
2013	O
Award	O
Judges	O
Patient	O
Group	O
Support	O
--	O
Pan-European	O
Patient	O
Group	O
Support	O
--	O
Austria	O
Patient	O
Group	O
Support	O
--	O
Belgium	O
Patient	O
Group	O
Support	O
--	O
Bosnia	O
Patient	O
Group	O
Support	O
--	O
Croatia	O
Patient	O
Group	O
Support	O
--	O
Cyprus	O
Patient	O
Group	O
Support	O
--	O
Czech	O
Republic	O
Patient	O
Group	O
Support	O
--	O
Denmark	O
Patient	O
Group	O
Support	O
--	O
Estonia	O
Patient	O
Group	O
Support	O
--	O
Finland	O
Patient	O
Group	O
Support	O
--	O
France	O
Patient	O
Group	O
Support	O
--	O
Germany	O
Patient	O
Group	O
Support	O
--	O
Greece	O
Patient	O
Group	O
Support	O
--	O
Hungary	O
Patient	O
Group	O
Support	O
--	O
Israel	O
Patient	O
Group	O
Support	O
--	O
Italy	O
Patient	O
Group	O
Support	O
--	O
Latvia	O
Patient	O
Group	O
Support	O
--	O
Lithuania	O
Patient	O
Group	O
Support	O
--	O
Macedonia	O
Patient	O
Group	O
Support	O
--	O
Netherlands	O
Patient	O
Group	O
Support	O
--	O
Norway	O
Patient	O
Group	O
Support	O
--	O
Poland	O
Patient	O
Group	O
Support	O
--	O
Portugal	O
Patient	O
Group	O
Support	O
--	O
Romania	O
Patient	O
Group	O
Support	O
--	O
Russia	O
Patient	O
Group	O
Support	O
--	O
Serbia	O
Patient	O
Group	O
Support	O
--	O
Slovakia	O
Patient	O
Group	O
Support	O
--	O
Slovenia	O
Patient	O
Group	O
Support	O
--	O
Spain	O
Patient	O
Group	O
Support	O
--	O
Sweden	O
Patient	O
Group	O
Support	O
--	O
Switzerland	O
Patient	O
Group	O
Support	O
--	O
Turkey	O
EFPIA	O
--	O
Austria	O
EFPIA	O
--	O
Bulgaria	O
EFPIA	O
--	O
Croatia	O
EFPIA	O
--	O
Cyprus	O
EFPIA	O
--	O
Czech	O
Republic	O
EFPIA	O
--	O
Estonia	O
EFPIA	O
--	O
Greece	O
EFPIA	O
--	O
Hungary	O
EFPIA	O
--	O
Latvia	O
EFPIA	O
--	O
Lithuania	O
EFPIA	O
--	O
Poland	O
EFPIA	O
--	O
Romania	O
EFPIA	O
--	O
Serbia	O
EFPIA	O
--	O
Slovakia	O
EFPIA	O
--	O
Slovenia	O
EFPIA	O
--	O
Ukraine	O
Newsroom	O
Media	O
Contacts	O
Multimedia	O
Library	O
Press	O
Releases	O
Events	O
Patients	O
Celgene	O
Patient	O
Support	O
Online	O
Patient	O
Resources	O
REMS	O
--	O
Pharmacy	O
Network	O
Glossary	O
Medical	O
Professionals	O
Partnerships	O
Business	O
Development	O
Partnerships	O
Global	O
Health	O
Partnerships	O
Advocacy	O
Partnerships	O
Suppliers	O
Suppliers	O
Form	O
Investors	O
Careers	O
Contact	O
Us	O
Contact	O
Us	O
--	O
Mobile	O
Shared	O
Services	O
Value	O
of	O
Medical	O
Innovation	O
PhRMA	O
Resources	O
Access	O
Innovation	O
Value	O
Terms	O
of	O
Use	O
,	O
Privacy	O
Policy	O
,	O
Site	O
Map	O
,	O
Community	O
Guidelines	O
,	O
Standing	O
in	O
the	O
GaaP	O
Facebook	O
Community	O
Guidelines	O
,	O
,	O
Celgene	O
Facebook	O
Community	O
Guidelines	O
,	O
,	O
The	O
Celgene	O
REMS	O
mobile	O
application	O
is	O
temporarily	O
unavailable	O
,	O
Celgene	O
Clinical	O
Trials	O
Information	O
,	O
Patients	O
'	O
Partners	O
--	O
ASH	O
2015	O
,	O
Patients	O
'	O
Partners	O
--	O
ASCO	O
2016	O
,	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
One	O
,	O
Patients	O
'	O
Partners	O
Registration	O
Webinar	O
--	O
Part	O
Two	O
,	O
Patients	O
'	O
Partners	O
Webinar	O
Registration	O
,	O
Publications	O
,	O
Instagram	O
Millefeuille	O
Movie	O
Community	O
Guidelines	O
,	O
,	O
Research	O
Oncology	O
,	O
https://www.celgene.com/about/leadership/senior-management/	O
